close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nuvation Bio Inc. Class A Common Stock (NY:NUVB)

5.690 -0.040 (-0.70%)
Streaming Delayed Price Updated: 9:39 AM EDT, Sep 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Nuvation Bio Inc. Class A Common Stock

< Previous 1 2 3 Next >
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
From Pomerantz LLP
Via GlobeNewswire
News headline image
NUVB Investors Have Opportunity to Join Nuvation Bio Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
From Pomerantz LLP
Via GlobeNewswire
News headline image
Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma
From Nuvation Bio
Via Business Wire
News headline image
Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference
From Nuvation Bio
Via Business Wire
News headline image
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan
From Nuvation Bio and Eisai
Via Business Wire
News headline image
Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Nuvation Bio
Via Business Wire
News headline image
Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology
From Nuvation Bio
Via Business Wire
News headline image
Nuvation Bio to Participate in Upcoming Investor Conferences
From Nuvation Bio
Via Business Wire
News headline image
Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire
News headline image
Nuvation Bio to Participate in Upcoming Investor Conferences
From Nuvation Bio
Via Business Wire
News headline image
Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma
From Nuvation Bio
Via Business Wire
News headline image
Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025
From Nuvation Bio
Via Business Wire
News headline image
Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer
From Nuvation Bio
Via Business Wire
News headline image
Nuvation Bio Receives Approval from Japan’s Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer
From Nuvation Bio
Via Business Wire
News headline image
Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer
From Nuvation Bio
Via Business Wire
News headline image
Nuvation Bio to Participate in Upcoming Investor Conferences
From Nuvation Bio
Via Business Wire
News headline image
Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update
From Nuvation Bio
Via Business Wire
News headline image
Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
From Nuvation Bio
Via Business Wire
News headline image
Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025
From Nuvation Bio
Via Business Wire
News headline image
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers
From Nuvation Bio
Via Business Wire
News headline image
U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer
From Nuvation Bio
Via Business Wire
News headline image
Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting
From Nuvation Bio Inc.
Via Business Wire
News headline image
Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Entrectinib at ISPOR 2025
From Nuvation Bio Inc.
Via Business Wire
News headline image
Nuvation Bio to Participate in Upcoming Investor Conferences
From Nuvation Bio Inc.
Via Business Wire
News headline image
Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire
News headline image
Nuvation Bio to Present at The Citizens Life Sciences Conference
From Nuvation Bio Inc.
Via Business Wire
News headline image
Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025
From Nuvation Bio Inc.
Via Business Wire
News headline image
Nuvation Bio to Present at the Jones Healthcare and Technology Innovation Conference
From Nuvation Bio Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.